Association of the 151042522 5101 with prostate cancer fisk, a study of cancer dissues,
primary tumor cultures and serum samples from a European Caucasian population.
Emily Toscano-Guerra ^{1,2,3*} , Valentina Maggio ¹ , Javier García ¹ , Maria Eugenia Semidey ⁴ , Ana Celma ⁵ , Juan Morote ⁵ , Inés de Torres ⁴ , Marina Giralt ² , Roser Ferrer ² , Rosanna
Paciucci ^{1,2*}
¹ Cell Signaling and Cancer Progression Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
² Biochemistry Service, Vall d'Hebron Hospital, Barcelona, Spain.
³ Universidad Peruana Cayetano Heredia, Lima, Perú.
⁴ Department of Pathology, Vall d'Hebron Hospital, Barcelona, Spain
⁵ Department of Urology, Vall d'Hebron Hospital, Barcelona, Spain
*Correspondence: Dr. Rosanna Paciucci, Biochemistry Service, Vall d'Hebron Hospital,
Barcelona, Spain. rospacbar@gmail.com; Dr. Emily Toscano-Guerra, Cell Signaling and
Cancer Progression Laboratory, Vall d'Hebron Institute of Research (VHIR), Barcelona,
Spain. ema.tg27@gmail.com

1 ABSTRACT

Prostate cancer (PCa) is the most common cancer in men and the third leading cause of 2 cancer death in Europe. The TP53 gene, the most frequently mutated gene in human 3 cancer, is a tumor suppressor gene with crucial functions in preventing tumor 4 5 development. The single nucleotide polymorphism rs1042522, characterized by the substitution of a proline (PRO) for an arginine (ARG) at the position 72 of the p53 protein 6 (P72R SNP), was studied in 12 primary tumor cultures from prostate biopsies of untreated 7 hormone-naïve patients (hnPCs) with aggressive-metastatic cancer (Gleason ≥ 8), 11 8 9 radical prostatectomies, and a cohort of 94 serums from patient with aggressive prostate cancer using DNA sequencing and melting curve analysis. The results identified a high 10 11 frequency of the P72R SNP in prostate cancer samples compared to the general European (non-cancer) population, suggesting a very significant association (p<0.0001) between 12 13 this SNP and the risk of prostate cancer with an odds ratio of 7.937 (IC 95% 5.37-11.00). The G allele (R72) was more frequent in patients with high Gleason scores (≥ 8) 14 suggesting its association to more undifferentiated-malignant PCa lesions. 15

16

17 INTRODUCTION

Prostate cancer (PCa), highly prevalent in developed countries, is the most frequent 18 cancer in men and the third cause of cancer death, after lung and colorectal, in Europe^{1,2}. 19 In the majority of the cases, the cancer is efficiently eradicated and cured by surgical 20 prostatectomy but late-diagnosed or metastatic aggressive cancers show a five-year 21 relative survival rate below 30%³. The tumor suppressor gene *TP53* plays a key role in 22 preventing tumor development. Not surprisingly it has been described as the most 23 commonly mutated gene in human cancers also in PCa⁴. Somatic TP53 mutations occur 24 more frequently as a later event, and are driver of the aggressive and metastatic cancer, 25 including PCa⁵. 26

Several hereditary genetic variations, found in approximately 5-20% of different cancer
types, are associated with pathogenic variants of genes such *BRCA2* and *ATM*. In PCa,
pathogenic germline variants of the *TP53* gene have been described with a relative risk
of 4.7-8.6, which is comparable with the frequencies described in those genes⁶.

Germline variants alleles known as a single-nucleotide polymorphisms (SNPs) are
present in >1% of the population, occur naturally, and are considered not to have a severe
impact on people health. However, many of these variants may impact the structure or the
function of the protein.

5 To study the characteristics of the aggressive metastatic prostate tumors that lead to incurable fatal disease, we established and partially characterized 12 primary tumor 6 cultures derived from prostate biopsies of untreated hormone-naïve patients (hnPCs) with 7 aggressive metastatic cancer. To identify potential predictive markers, the hnPCs cultures 8 9 were screened for the presence of mutations in driver genes by DNA sequencing. Here, we describe the identification of the TP53 gene variant allele rs1042522 in the majority 10 11 of the hnPCs analyzed. The presence of this SNP was confirmed in a cohort of 11 radical prostatectomy tissues and 94 serum samples from Caucasian patients with prostate cancer. 12 13 The association of the variant allele with prostate cancer risk was investigated using comparisons with the healthy (non-cancer) European (non-Finnish) population from 14 15 GnomAD v2.1.1.

16 MATERIALS AND METHODS

17 Prostate primary cultures (hnPCs) from hormone-naïve patients

Primary cultures from prostate tumor needle biopsies of hormone-naïve patients (i.e., 18 without previous treatments) were established in our laboratory from a cohort of patients 19 selected for (i) high levels of serum PSA (>50 ng/mL), (ii) positive digital rectal 20 examination (DRE), and (iii) Gleason ≥ 8 . hnPCs were cultured at 37°C in atmosphere of 21 5% CO2, with complete DMEM-F12 medium, containing: 2 mM of L-Glutamine, 100U 22 of penicillin/mL, 100 µg streptomycin/mL, 0.1 mM of non-essential amino acids, 1 mM 23 of sodium pyruvate and 7% fetal bovine serum, with Supplement 1X, human FGF-10 (10 24 ng/µL), human EGF (20 ng/µL), and Vitamin A and E (200 ng/µL). Growth factors and 25 vitamins were added freshly whereas supplements were prepared and stored at -20°C until 26 its used. Supplement (100X) was prepared in DMEM-F12 containing glucose (6 mg/mL), 27 transferrin (1000 µg/mL), human insulin (2.500 µg/mL), putrescine (97 µg/mL), sodium 28 29 selenite (30 μ M) and hydrocortisone (100 μ M).

30 Radical prostatectomies (RPs) samples

1 Eleven radical prostatectomies (RPs) samples from patients with low-grade operable

2 tumors (Gleason \leq 7) were used to compare with hnPCs. Samples were collected by the

3 Service of Urology of the Hospital Vall d'Hebron (HVH), preserved in Optimal Cutting

4 Temperature compound (OCT) and stored at -80 °C until frozen sectioning.

5 Serum samples from PCa patients

A cohort of 94 serum samples from patients with diagnosis of prostate cancer were
selected with the criteria: PSA values ≥ 50 ng/mL, males southern European. The study
was performed with surplus serum samples from routinely tested patients at the
Biochemistry Service of HVH, following protocols reviewed and approved by the HVH
Institutional Review Board (Medical Research Ethics Committee, protocol number
PR(AG) 96/2015).

Serum samples from blood collected in SST yellow tubes containing separator gels, were centrifugated at 3,500 rpm for 15 minutes at 4°C. The resulting serum was collected in 2 mL tubes, properly labeled and codified in the biobank system, were then stored at -80°C. Sample processing was performed according to the scientific and ethical guidelines approved by biomedical research law (Decret 1716/2011).

17 DNA extraction

The genomic DNA from hnPCs and RP was extracted using the DNeasy mini kit (Qiagen) 18 following the manufacturer's guidelines. For the frozen tissue sections from RPs, samples 19 in criotubes were previously mixed with 180 µL of ATL buffer, then homogenized by 20 passing it through a 20-gauge needle attached to an RNase-free syringe about 5-10 times. 21 Successively, samples were incubated with Proteinase K, at 56°C (1 hour) vortexing every 22 20 minutes during the incubation period. For genomic DNA extraction from serum 23 samples, the MagNA Pure 24 Instrument, and total Isolation Kite (Roche) were used, a 24 fully automated system based on using magnetic glass particles technology (MGP), that 25 allows the processing of up to 24 samples in about 70 minutes. 26

27 DNA sequencing

The presence of the variant rs104252 of the *TP53* gene was first identified in hnPCs and RPs by analysis of the complementary DNA (cDNA) using RNA reverse transcription (RT) and Sanger sequencing. cDNA synthesis was done with RNA (1 μ g) previously verified for good quality (RIN \geq 7), using the NZY M-MuLV kit (NZY Tech) and the

- 1 2720 Thermocycler (Applied Biosystems), then the cDNAs were sequenced using Sanger
- 2 technology.

3 DNA genotyping

- 4 To analyze the Pro72Arg SNP of *TP53* genotyping was conducted for all samples using
- 5 the Melting Curve analysis with a customized Light SNiP assay (TIB MOLBIOL) on a
- 6 LightCycler 480 II instrument (Roche). Reactions were carried out in a final volume of
- 7 20 μL, comprising 2.0 μL of LightCycler FastStart DNA Master HybProbe mix (Roche),
- 8 1.0 μL of LightSNiP mix, 3 mM MgCl2, and 50 ng of DNA. The ThermoCycler was set
- 9 up under the conditions outlined in Table 1. Subsequently, the melting curves were
- 10 assessed using the Melt Curve Genotyping software (Roche).

11 Control group

12 To study the association of the SNP P72R with prostate cancer, the frequencies found in

- 13 the (non-cancer) European (non-Finnish) population from GnomAD v2.1.1, containing
- 14 134 187 samples, were used as a control group.

15 Gleason score and grade groups

The Gleason score is a classification system that assesses the aggressiveness of prostate 16 tumors based on the architecture of the cancerous tissues and the degree of cells 17 18 differentiation as observed under a microscope. This score, which ranges from 6 to 10, is the sum of two histological patterns (the most common plus the highest grade) within a 19 20 single tissue sample (Table 2). To better understand and describe the cancer aggressiveness, the Gleason score is adjusted into a grade group encompassing values 21 22 from 1 to 5. The correlation between the score and its respective group, is shown in Table 23 2.

24 Statistics

Analysis of associations of frequencies and proportions were done using Contingency tables and Fisher's test. Values were considered significant when $p \le 0.05$. These analyses were conducted using GraphPad Prism 9 software. Data and image analyses were performed using Circos tool (http://circos.ca/).

29 RESULTS

30 The *TP53* gene variant allele rs1042522

More than 20 different SNPs have been described in the *TP53* gene⁷, including the variant rs1042522, or P72R, in the amino acid 72 of p53 (Figure 1A). This variant contains a guanine at position 357 in codon 72 (CGC), a modification that results in a change of the encoded amino acid from proline (CCC) to arginine (R or ARG). (Figure 1B). Figure 1C shows that the arginine induces a decrease in hydrophobicity (turquoise bars) relative to the most abundant proline (P or PRO), which may impact the interaction of the p53 protein with other ligands (CCAR2 or HRMT1L2).

8 P72R and allele frequencies in primary prostate tumor cultures and cancer tissues

To study the potential role of TP53 mutations in the aggressiveness of unresectable 9 prostate tumors, we examined 12 primary tumor cultures (hnPCs) by cDNA sequencing 10 and identified a mutation at position 357 that changed a cytosine to a guanine. This change 11 is not a somatic mutation but corresponds to the allelic variant rs1042522. The frequency 12 found by cDNA sequencing for the ARG variant was 0.82 (9/11) compared to the PRO 13 variant frequency of 0.18 (2/11) (Table 3). To confirm these results, the 12 primary 14 cultures plus 11 prostatectomy tissue samples from different prostate cancer patients were 15 16 genotyped using gDNA melting curve analysis (Table 3, Figure 2A). In hnPCs, 2 17 homozygotes for cytosine (C, proline), 6 homozygotes for guanine (G, arginine), and 4 heterozygotes that predominantly expressed ARG were found. In the RP tissues, 4 18 19 homozygotes for cytosine, 5 homozygotes for guanine, and 4 heterozygotes expressed predominantly ARG. The total frequencies of C and G in primary tumor cultures were 20 21 0.33 and 0.67, respectively, while in RP tissues the frequency of C was 0.45 and of G 0.55, indicating that primary tumor cultures have a higher incidence of the SNP P72R 22 compared to tumor tissues from prostatectomies. These results would suggest that 23 prostate cancers derived from patients with inoperable tumors may differ from cancers 24 that can be cured by surgery. 25

26 **P72R SNP is associated with prostate cancer risk.**

To validate the above results, the serum of 94 patients with prostate cancer (PSA \geq 50 ng/ml) were genotyped (Figure 2A). P72R is a controversial SNP, found at different frequencies across populations (worldwide), although the majority of sub-populations show lower frequencies (Figure 2B). In the selected European (non-Finnish) non-cancer population the frequency of the G allele was 26.3%, while the frequency of the C allele was 73.6% (Figure 2B). In the serum samples, the frequency of homozygotes for ARG (hARG) was 53.38% (53/94), homozygotes for PRO (hPRO) were 8.58% (8/94) and

heterozygotes was 35.10% (33/94) (Figure 2C). The allele frequencies observed in our 1 cohort of serum, hnPCs, and prostatectomy tissues were then compared with the (non-2 cancer) European (non-Finnish) control population (Figure 2D). The results show 3 significant differences in the recurrence rate of the P72R SNP in all samples compared to 4 the control population, suggesting an association of the P72R SNP with prostate cancer. 5 The significance of this association assessed by a contingency analysis (Fisher's test), 6 7 showed a very significant association between the P72R SNP and prostate cancer in all samples analyzed, with a frequency of 73.93% for the G allele and an odds ratio of 7.937 8 9 (IC 95% 5.37-11.00) for serum samples (p<0.0001) (shown in **Table 4**).

10 P72R SNP is not significantly associated with high Gleason tumors.

The ability of a mutant p53 protein to neutralize apoptosis and transform cells in 11 cooperation with EJ-Ras is enhanced when codon 72 encodes ARG (R72)⁸. This R72 12 variant was reported to be able to bind more efficiently and inactivate PGC-1 α^4 , a 13 transcriptional target of p53-induced apoptosis in prostate cancer cells, thereby promoting 14 cell invasion and metastasis⁴. These observations support our findings that a higher R72 15 16 allele frequency is present in more aggressive PCa tumors. To study whether the Gleason score (grade) of all genotyped patients was associated to higher frequency of the R72 17 allele, we used the Gleason grading group (1 to 5 instead of 6 to 10) and divided them 18 into 2 different groups: low - medium aggressive tumors (Gleason grade 1 - 3) and highly 19 aggressive tumors (Gleason grade 4 - 5). Patients were genotyped as hARG, hPRO, and 20 heterozygous (ARG-PRO). Data from the cohort of 94 serum patients were plotted on a 21 Circos plot according to Gleason group. Figure 3A shows the distribution of patient's 22 proportions in each Gleason group. Although a marked lower proportion of the P72 allele 23 and a remarkably higher frequency of the R72 allele are visible in high Gleason tumors, 24 these differences did not reach statistical significance (p-value = 0.2867) (Figure 3A and 25 26 **3B)**.

27 DISCUSSION

The tumor suppressor gene *TP53*, reported mutated with a high frequency (53.3%) in aggressive mCRPC^{9,4}, was the focus of this investigation. The finding that 9 out of 12 primary tumor cultures from patients with aggressive metastatic PCa had a p53 protein with arginine (CGC) at codon 72 while only 2 cultures had a proline (CCC), was intriguing. An initial explanation for the enrichment of the R72 variant in hnPCs from

cancer tissues was the Loss of Heterozygosity (LOH), particularly studied in exon 4 that 1 includes the codon 72 of the protein. In fact, loss of the Proline (C) allele and preferential 2 retention of the Arginine (G) allele was described in primary tumors and metastatic tissues 3 of squamous cell carcinoma of vulva¹⁰, head and neck¹¹, colorectal tumors¹², and lung 4 cancer¹³. In addition, a recent meta-analysis study using the TCGA pan-cancer database 5 and patients selected for the P72R heterozygosity, reported that 31% (127/409) of 6 heterozygotes had lost the P72 allele in the corresponding tumor tissue¹⁴ indicating that 7 the G allele is preferentially selected for tumor development, possibly due to enhanced 8 p73-induced apoptosis¹⁵ and the modulation of tumor metabolism by regulating PGC-9 $1\alpha^{16}$. Although proper LOH screening was not performed in our cancer cohort, the 10 genotyping analysis of serum samples, that showed a similar frequency of the R72 variant 11 compared to hnPCs and cancer tissues from prostatectomy, suggested that it is more likely 12 13 to be an association with PCa risk.

Because of the high frequency of arginine in the genotyped DNA from hnPCs and RPs 14 was significantly different from the European non-cancer population, a larger number of 15 samples (serum) from patients with prostate cancer were examined. The results confirmed 16 the high frequency of the guanine (C to G) at position 357 compared to a control European 17 non-cancer population selected from the GnomAD v2.1, indicating a very significant 18 association (p<0.0001) of this SNP and prostate cancer risk, with odds ratio of 7.937 (IC 19 95% 5.37-11.00). Several reports have described a similar significant association of the 20 R72 SNP with the risk of developing cutaneous melanoma, breast cancer, or prostate 21 cancer ^{17–20}. The study on PCa compared 187 Iranian patients with 185 control individual 22 negative for cancer²⁰. Although the frequency of G allele in cancer patients (65.77%) was 23 not as high as we report here (73.93%), the association was statistically significant 24 compared to the control (p < 0.05). 25

It is worth noting that several reports have shown controversial results^{21–23} or failed to 26 demonstrate a significant association between the rs1042522 variant and the risk of any 27 type of cancer^{24–28}, probably due to limited sample size or selection bias. For example, in 28 a colorectal cancer study in the Northern-European population, no significant association 29 30 between the presence of the SNP and the risk of cancer was reported²⁹, but the healthy control samples selected had a high frequency of ARG allele (61%) in contrast to the 31 estimated 26% frequency of the (non-cancer) European population from GnomAD v2.1.1 32 (Figure 2). Similar to our findings, one study in prostate cancer reported an association 33

between Pro/Pro and a lower risk of prostate cancer³⁰. However, a number of other reports
 have shown conflicting results^{30-32,27,33-35}. Appropriate representativeness in control
 samples is necessary for accurate results.

Bevond these conflicting findings regarding the ARG frequency at codon 72 of p53, it is 4 5 crucial to consider the potential impact of this variant on cancer development, although its full understanding is not clear. Studies in mice revealed that the presence of the R72 6 variant shows higher incidence of mammary tumors³⁶. In addition, this variant associated 7 to increased phosphorylation of p53 and enhanced transactivation of CDKN1A (p21^{WAF1}) 8 9 in response to starving, with consequent augmented growth arrest but reduced apoptosis, a situation that favors survival³⁷. Furthermore, TP53 mutations tend to preferentially 10 occur in the R72 allele. In the presence of a mutant TP53 (e.g. R175H, R273H, and 11 A138V) harboring the R72 SNP, an enhanced capacity for migration, invasion, and 12 metastasis in various cancer cell lines, including PCa, has been reported¹⁶. These 13 observations provide strong evidence that ARG at codon 72 affects the tumor suppression 14 activity of p53. 15

Although no significant association of P72R SNP with the Gleason score was found in 16 our study, the G allele (R72) was more frequent in patients with high Gleason (≥ 8 , group 17 4-5) suggesting a possible association to more undifferentiated-malignant PCa lesions 18 (Figure 3B). A few studies also evaluated the association between this polymorphism and 19 tumor grades and found no significant association with clinical stage or Gleason grade in 20 PCa^{33,34,38,39}. One study identified a link with a modest influence of this SNP and shorter 21 biochemical recurrence (BCR) after radical prostatectomy³⁵. Another study in the 22 Japanese population³¹, observed a particularly high frequency of the ARG allele in 23 24 patients with metastases and those with a high-Gleason score (≥ 8). However, this study analyzed the association using the arginine allele as a reference, meaning they calculated 25 the significance level between the Pro/Pro and Pro/Arg genotype compared to arginine. 26 As expected, they found no significant difference, as proline did not differ significantly 27 from the control group. 28

To validate and extend our findings, further investigation with a larger number of samples and consideration of the family history of prostate cancer would be needed. Nevertheless, our present results suggest that a simple but powerful test (gDNA assessment for the P72R SNP) may be useful for the early identification of patients at risk of aggressive metastatic prostate cancer, allowing clinicians to intervene at an early stage.

- 1 Acknowledgments: The authors extend their gratitude to the Biochemistry service from
- 2 Hospital Vall d'Hebron, Barcelona-Spain, for technical support.

3 Author contributions

- 4 Contributors ETG, and RP conceived and designed the study. ETG, VM, MES, AC and
- 5 MG collected clinical samples and data. ETG, VM and JG, performed experiments, and
- 6 analyzed data. ETG and RP generated figures and tables and wrote the manuscript. RP,
- 7 JM, IT and RF contributed to data interpretation and critically reviewed the manuscript.
- 8 All authors approved the final manuscript for submission.
- 9 The authors declare no conflicts of interest.

1 REFERENCES

- 2 1. Ferlay, J. *et al.* Global Cancer Obeservatory: Cancer Today.
- 3 http://gco.iarc.fr/today/home (2020).
- 4 2. Wang, L. et al. Prostate Cancer Incidence and Mortality: Global Status and
- 5 Temporal Trends in 89 Countries From 2000 to 2019. *Frontiers in Public Health* **10**,
- 6 (2022).
- 7 3. Prostate Cancer Statistics. *Cancer.Net* https://www.cancer.net/cancer-
- 8 types/prostate-cancer/statistics (2023).
- 9 4. McCann, J. J. *et al.* Mutant p53 elicits context-dependent pro-tumorigenic
 phenotypes. *Oncogene* 41, 444–458 (2022).
- 5. Arora, K. & Barbieri, C. E. Molecular Subtypes of Prostate Cancer. *Curr Oncol Rep*20, 58 (2018).
- Maxwell, K. N. *et al.* Inherited TP53 Variants and Risk of Prostate Cancer.
 European Urology 81, 243–250 (2022).
- T, B., Jld, P. & Me, M. Common genetic variants in the TP53 pathway and their
 impact on cancer. *Journal of molecular cell biology* 11, (2019).
- Marin, M. C. *et al.* A common polymorphism acts as an intragenic modifier of
 mutant p53 behaviour. *Nat Genet* 25, 47–54 (2000).
- Robinson, D. *et al.* Integrative clinical genomics of advanced prostate cancer. *Cell* 161, 1215–1228 (2015).
- 10. Brooks, L. A. *et al.* Preferential retention of codon 72 arginine p53 in squamous cell
 carcinomas of the vulva occurs in cancers positive and negative for human
 papillomavirus. *Cancer Res* 60, 6875–6877 (2000).
- 24 11. Schneider-Stock, R. *et al.* Retention of the arginine allele in codon 72 of the p53
- 25 gene correlates with poor apoptosis in head and neck cancer. *Am J Pathol* **164**,
- 26 1233–1241 (2004).
- 27 12. Schneider-Stock, R. *et al.* Selective Loss of Codon 72 Proline p53 and Frequent
- 28 Mutational Inactivation of the Retained Arginine Allele in Colorectal Cancer.
- 29 *Neoplasia* **6**, 529–535 (2004).

1 2 3 4	 Papadakis, E. D., Soulitzis, N. & Spandidos, D. A. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained tumours arising in Arg/Pro germline heterozygotes. <i>Br J Cancer</i> 87, 1013–1018 (2002). 	l in
5 6	 De Souza, C. <i>et al.</i> Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer. <i>J Natl Cancer Inst</i> 113, 1246–1257 (2021). 	
7 8	 Marin, M. C. <i>et al.</i> A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. <i>Nat Genet</i> 25, 47–54 (2000). 	
9 10	 Basu, S. <i>et al.</i> Mutant p53 controls tumor metabolism and metastasis by regulatin PGC-1α. <i>Genes & Development</i> 32, 230 (2018). 	g
11 12	 Shen, H. <i>et al.</i> p53 Codon 72 Arg Homozygotes Are Associated with an Increased Risk of Cutaneous Melanoma. <i>J Invest Dermatol</i> 121, 1510–1514 (2003). 	l
13 14 15	 Volodko, N. <i>et al.</i> TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. <i>World J Gastroenterol</i> 2 10358–10366 (2015). 	21,
16 17	19. Dia, Y. <i>et al.</i> Arg Allele of P53 Gene Codon72 is a Risk Factor for Breast Cancer Senegalese Women. <i>Journal of Molecular and Genetic Medicine</i> 11 , (2017).	in
18 19 20	 Doosti, A. & Dehkordi, P. G. The p53 codon 72 polymorphism and association to prostate cancer in Iranian patients. <i>African Journal of Biotechnology</i> 10, 12821–12825 (2011). 	
21 22 23	 Ezzikouri, S. <i>et al.</i> The Pro variant of the p53 codon 72 polymorphism is associat with hepatocellular carcinoma in Moroccan population. <i>Hepatology Research</i> 37, 748–754 (2007). 	ed
24 25 26	 22. Mohana Devi, S. <i>et al.</i> Analysis of Genetic Damage and Gene Polymorphism in Hepatocellular Carcinoma (HCC) Patients in a South Indian Population. <i>Dig Dis</i> 58, 759–767 (2013). 	Sci
27 28	23. Son, M. S. <i>et al.</i> Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. <i>Gene</i> 524 , 156–160 (2013).	

1 2 3	 24. Tang, NP., Wu, YM., Wang, B. & Ma, J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. <i>European Journal of Surgical Oncology (EJSO)</i> 36, 431–438 (2010).
4 5	25. Weng, Y. <i>et al.</i> p53 codon 72 polymorphism and Hematological Cancer Risk: An Update Meta-Analysis. <i>PLOS ONE</i> 7 , e45820 (2012).
6 7	26. Ye, J., Li, XF., Wang, YD. & Yuan, Y. Arg72Pro Polymorphism of TP53 Gene and the Risk of Skin Cancer: a Meta-Analysis. <i>PLOS ONE</i> 8 , e79983 (2013).
8 9	27. Zhang, L. <i>et al.</i> Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis. <i>J Biomed Res</i> 25 , 25–32 (2011).
10 11 12	28. Xu, T., Xu, ZC., Zou, Q., Yu, B. & Huang, XE. P53 Arg72Pro polymorphism and bladder cancer riskmeta-analysis evidence for a link in Asians but not Caucasians. <i>Asian Pac J Cancer Prev</i> 13, 2349–2354 (2012).
13 14 15	 29. Krüger, S. <i>et al.</i> The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). <i>Journal of Medical Genetics</i> 42, 769–773 (2005).
16 17	30. Henner, W. D. <i>et al.</i> Association of codon 72 polymorphism of p53 with lower prostate cancer risk. <i>Prostate</i> 49 , 263–266 (2001).
18 19	31. Suzuki, K. <i>et al.</i> A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. <i>J Biomed Sci</i> 10 , 430–435 (2003).
20 21 22	32. Li, M. S., Liu, J. L., Wu, Y., Wang, P. & Teng, H. Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk. <i>Genet</i> <i>Mol Res</i> 10, 2924–2933 (2011).
23 24	33. Lu, Y. <i>et al.</i> Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis. <i>Tumor Biol.</i> 35 , 3997–4005 (2014).
25 26	34. Sivoňová, M. K. <i>et al.</i> Association of p53 and p21 polymorphisms with prostate cancer. <i>Biomedical Reports</i> 3 , 707–714 (2015).
27 28 29	35. Duncan, A. <i>et al.</i> Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men. <i>Biomedicines</i> 11, 1404 (2023).

1	36. Gunaratna, R. T. et al. Dynamic role of the codon 72 p53 single-nucleotide
2	polymorphism in mammary tumorigenesis in a humanized mouse model. Oncogene
3	38 , 3535–3550 (2019).
4	37. Kung, CP., Liu, Q. & Murphy, M. E. The codon 72 polymorphism of p53
5	influences cell fate following nutrient deprivation. Cancer Biology & Therapy 18,
6	484–491 (2017).
7	38. Babaei, F. et al. The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate
8	Cancer among Iranian Patients. Iran J Public Health 43, 453-459 (2014).
9	39. Aydin, M. et al. Lack of evidence of HPV etiology of prostate cancer following
10	radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with
11	prostate cancer. Int Braz J Urol 43, 36–46 (2017).
12	
13	

1 FIGURE LEGENDS

2 Figure 1. SNP P72R in the TP53 gene. A) The canonic transcript for variant rs1042522.

3 The TP53 transcript 201 consists of 11 exons encoding a protein of 393 amino acids

4 including exons 2 to the 5' region of exon 11. B) The SNP P72R (black arrows)

- 5 polymorphic variants, Proline (P) encoded by the triplet CCC, and Arginine (R) encoded
- 6 by CGC at position 357 of the coding strand. C) The change in the hydrophobic profile
- 7 of variant rs1042522 (red arrow) when P is changed to R, a polar-positive amino acid.
- 8 Figures from Benchling.com.



9

Figure 2: Allele frequencies in the European population and in prostate cancer 10 11 samples. A) Representative melting curves from serum samples. Peaks of absorbance at different dissociation temperatures. Left panel: homozygous samples with cytosine in 12 both strands show a dissociation peak at 68°C. Center panel: homozygous samples with 13 guanine in both strands show a dissociation peak at 60°C. Right panel: heterozygous 14 samples with cytosine and guanine are identified by both peaks. B) Global frequency for 15 the allele rs1042522. Allele G has a lower frequency in all sub populations except for the 16 African population. Data and Images from Ensemble.org. C) rs1042522 frequencies in 17 serum samples from patients with prostate cancer. D) rs1042522 frequencies in primary 18 19 tumor cultures (hnPCs), serum samples, radical prostatectomy biopsies, compared to the European population. 20



2

3 Figure 3. Distribution of the rs1042522 variant in 94 prostate cancer patients according to Gleason grade. A) Circos plot displaying the distribution of the P72R 4 genotypes according to patient Gleason score. B) Distribution of the SNP in low Gleason 5 grade (1-3) and high Gleason grade (4-5); the contingency analysis of these proportions 6 did not yield significant results. Gleason grade 1: Gleason score ≤ 6 ; Gleason grade 2-3: 7 Gleason score = 7; Gleason grade 4: Gleason score = 8; Gleason grade 5: Gleason score 8 9 ≥9.



TABLES: 1

2 Table 1. Cycling conditions for Melting curve analysis

3

Phase.	Cycles	Temperature	Hold	Ramp rate (°C/s)
Denaturation	1	95	10 min	4.6
		95	10 sec	4.6
Cycling	45	60	10 sec	2.4
		72	15 sec	4.6
		95	30 sec	4.6
Melting	1	40	2 min	2.0
		75	0 sec	-
Cooling	1	40	30 sec	2.0

4

5

Table 2. Prostate cancer classification in groups according to Gleason pattern. 6

Patterns*	Score	Group	Significance		
1+2, 3+2, 3+3	≤ 6	1	Low-grade cancer		
3+4	7	2	Medium-grade cancer		
4+3	7	3	Medium-grade cancer		
3+5, 4+4, 5+3	8	4	High-grade cancer		
4+5, 5+4	9	5	High-grade cancer		
5+5	10	5	High-grade cancer		
*Gleason patterns indicate the grade of tissue differentiation.					

¹Small, uniform glands, well differentiated.

²More stroma between glands, well differentiated.

³Distinctly infiltrative margins, moderately differentiated.

⁴Irregular masses of neoplastic glands, poorly differentiated.

⁵Only occasional gland formation, poorly differentiated/anaplastic tissue.

Table 3. P72R genotyping in primary cultures and radical prostatectomy tissues 1

Sanger sequencing				LightS	NiP assay
SAMPLE	E cDNA		Expressed	gDNA	
			Aminoacid		
hnPC01	CCC	TCCCCCCG	Proline	СС	Homozygous
		MMM			Proline
hnPC06	CCC		Proline	СС	Homozygous
					Proline
hnPC02	CGC		Arginine	GG	Homozygous
hnPC03	CGC	•	Arginine	GG	Arginine
hnPC08	CGC	TCCCCGCG	Arginine	GG	_
hnPC09	CGC	1 //////////	Arginine	GG	_
hnPC10	CGC		Arginine	GG	_
hnPC12	CGC		Arginine	GG	_
hnPC04	CGC	TCCCCGCG	Arginine	CG	Heterozygous
hnPC05	CGC	MMM	Arginine	CG	
hnPC11	CGC		Arginine	CG	_
hnPC07	N.D	N.D	N.D	CG	_
RP11D	CGC		Arginine	CG	Heterozygous
RP14D	CGC		Arginine	GG	Homozygous
RP17B	CGC		Arginine	GG	Homozygous
RP18F	CGC		Arginine	GG	Homozygous
RP21D	CGC		Arginine	GG	Homozygous
RP23D	CCC		Proline	СС	Homozygous
RP36E	CCC		Proline	СС	Homozygous
RP37A	CGC		Arginine	CG	Heterozygous
RP40B	CCC		Proline	CC	Homozygous
RP63A	CGC		Arginine	GG	Homozygous
RP68C	CCC		Proline	CC	Homozygous

1 Table 4. Analysis of the association of the rs1042522 variant and prostate cancer

2

Serum samples	Prostate Cancer, n (%)	GnomAD Non-cancer, n (%)	Odds Ratio (95% CI)*	P- value*	
Arginine (G allele)	139 (0.74)	31021 (0.26)	7.937 (5.73–11.00)		
Proline (C allele)	49 (0.26)	86797 (0.74)		< 0.0001	
Total	188	117818			
hnPCs samples			· · · ·		
Arginine (G allele)	16 (0.67)	31021 (0.26)	5.596 (2.395– 13.080)	<0.0001	
Proline (C allele)	8 (0.33)	86797 (0.74)		<0.0001	
Total	24	117818			
RPs samples		I			
Arginine (G allele)	12(0.55)	31021 (0.26)	3.358(1.451-7.772)		
Proline (C allele)	10(0.45)	86797 (0.74)		0.0058	
Total	22	117818			
Contingency table for the association between the P72R SNP and prostate cancer. The selected European (non-Finnish) non-cancer population from GnomAD was used as a control.					

*Odds ratio and p-values were calculated with the Fisher's Test.

3

4

TP53-201 (ENST00000269305) (2512 bp)





в

1000 Genomes Project Phase 3 allele frequencies



EUR sub-populations



С

	Allele	frequency in seru	ım samp	oles
	Homozygotes	Heterozygotes	Total	Frequency
G	106	33	139	0.739361
С	16	33	49	0.260638
			188	1



D

